Common polymorphism in the cannabinoid type 1 receptor gene (CNR1) is associated with microvascular complications in type 2 diabetes.
暂无分享,去创建一个
[1] H. Flynn,et al. Genetics and diabetic retinopathy. , 2012, Current diabetes reviews.
[2] A. McAinch,et al. Endocannabinoids and the renal proximal tubule: an emerging role in diabetic nephropathy. , 2012, The international journal of biochemistry & cell biology.
[3] E. Ntzani,et al. Genetic risk factors for type 2 diabetes: insights from the emerging genomic evidence. , 2012, Current vascular pharmacology.
[4] D. Petrovič,et al. GSTT1 Null Genotype Is a Risk Factor for Diabetic Retinopathy in Caucasians with Type 2 Diabetes, whereas GSTM1 Null Genotype Might Confer Protection against Retinopathy , 2012, Disease markers.
[5] K. Mackie,et al. Cannabinoid 1 Receptor Promotes Cardiac Dysfunction, Oxidative Stress, Inflammation, and Fibrosis in Diabetic Cardiomyopathy , 2012, Diabetes.
[6] R. González-Sarmiento,et al. Cannabinoid receptor 1 gene is associated with alcohol dependence. , 2012, Alcoholism, clinical and experimental research.
[7] B. Cravatt,et al. Hyperglycemia induces apoptosis via CB1 activation through the decrease of FAAH 1 in retianl pigment epithelial cells , 2012, Journal of cellular physiology.
[8] P. Pacher,et al. The endocannabinoid system and plant-derived cannabinoids in diabetes and diabetic complications. , 2012, The American journal of pathology.
[9] Wenchao Hu,et al. G1359A Polymorphism in the Cannabinoid Receptor-1 Gene is Associated With the Presence of Coronary Artery Disease in Patients With Type 2 Diabetes , 2012, Journal of Investigative Medicine.
[10] Barry I Freedman,et al. Genetic and environmental factors associated with type 2 diabetes and diabetic vascular complications. , 2012, The review of diabetic studies : RDS.
[11] S. Hadjadj,et al. Allelic variations in superoxide dismutase-1 (SOD1) gene are associated with increased risk of diabetic nephropathy in type 1 diabetic subjects. , 2011, Molecular genetics and metabolism.
[12] C. Fox,et al. Variants at the Endocannabinoid Receptor CB1 Gene (CNR1) and Insulin Sensitivity, Type 2 Diabetes, and Coronary Heart Disease , 2011, Obesity.
[13] D. Petrovic,et al. A review of oxidative stress related genes and new antioxidant therapy in diabetic nephropathy. , 2011, Cardiovascular & hematological agents in medicinal chemistry.
[14] P. Franks. Gene × Environment Interactions in Type 2 Diabetes , 2011, Current diabetes reports.
[15] L. Devi,et al. The Highs and Lows of Cannabinoid Receptor Expression in Disease: Mechanisms and Their Therapeutic Implications , 2011, Pharmacological Reviews.
[16] D. D. de Luis,et al. Relation of G1359A polymorphism of the cannabinoid receptor (CB1) gene with metabolic syndrome by ATP III classification , 2011, Diabetes/metabolism research and reviews.
[17] P. Pacher,et al. Cannabinoid 1 receptor activation contributes to vascular inflammation and cell death in a mouse model of diabetic retinopathy and a human retinal cell line , 2011, Diabetologia.
[18] A. Vasku,et al. A common variation in the cannabinoid 1 receptor (CNR1) gene is associated with pre-eclampsia in the Central European population. , 2011, European journal of obstetrics, gynecology, and reproductive biology.
[19] J. Petrie,et al. Implications of genome wide association studies for the understanding of type 2 diabetes pathophysiology. , 2011, Biochemical pharmacology.
[20] Yanjun Zhang,et al. G1359A polymorphism in the cannabinoid receptor-1 gene is associated with coronary artery disease in the Chinese Han population. , 2011, Clinical laboratory.
[21] S. Maeda,et al. Genetics of type 2 diabetes: the GWAS era and future perspectives [Review]. , 2011, Endocrine journal.
[22] S. K. Lim,et al. Cannabinoid receptor 1 mediates palmitic acid‐induced apoptosis via endoplasmic reticulum stress in human renal proximal tubular cells , 2010, Journal of cellular physiology.
[23] Wenchao Hu,et al. G1359A polymorphism in the cannabinoid receptor-1 gene is associated with metabolic syndrome in the Chinese Han population. , 2010, Archives of medical research.
[24] A. Howlett,et al. CB(1) cannabinoid receptors and their associated proteins. , 2010, Current medicinal chemistry.
[25] S. Brand,et al. The Cannabinoid 1 Receptor (CNR1) 1359 G/A Polymorphism Modulates Susceptibility to Ulcerative Colitis and the Phenotype in Crohn's Disease , 2010, PloS one.
[26] M. Rastaldi,et al. Cannabinoid Receptor 1 Blockade Ameliorates Albuminuria in Experimental Diabetic Nephropathy , 2010, Diabetes.
[27] S. Steffens,et al. The emerging role of the endocannabinoid system in cardiovascular disease , 2009, Seminars in Immunopathology.
[28] T. Hansen,et al. Endocannabinoid receptor 1 gene variations increase risk for obesity and modulate body mass index in European populations. , 2008, Human molecular genetics.
[29] J. Herbert,et al. Blockade of cannabinoid CB1 receptors improves renal function, metabolic profile, and increased survival of obese Zucker rats. , 2007, Kidney international.
[30] T. Frayling. Genome–wide association studies provide new insights into type 2 diabetes aetiology , 2007, Nature Reviews Genetics.
[31] D. Tregouet,et al. Genetic variations at the endocannabinoid type 1 receptor gene (CNR1) are associated with obesity phenotypes in men. , 2007, The Journal of clinical endocrinology and metabolism.
[32] I. Matias,et al. Changes in endocannabinoid and palmitoylethanolamide levels in eye tissues of patients with diabetic retinopathy and age-related macular degeneration. , 2006, Prostaglandins, leukotrienes, and essential fatty acids.
[33] Y. Khalifa,et al. Neuroprotective and blood-retinal barrier-preserving effects of cannabidiol in experimental diabetes. , 2005, The American journal of pathology.
[34] B. Peterlin,et al. Aldose reductase (AC)n gene polymorphism and susceptibility to diabetic retinopathy in Type 2 diabetes in Caucasians. , 2005, Journal of diabetes and its complications.
[35] G. Uhl,et al. Human cannabinoid receptor 1: 5′ exons, candidate regulatory regions, polymorphisms, haplotypes and association with polysubstance abuse , 2004, Molecular Psychiatry.